Floatz logo

CLEMASTIN

Schizophrenia

LMU KlinikumSmall moleculePhase 2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
65/ 100

Competitive context

144 Active assets in the Schizophrenia cohort.

Asset / SponsorPhaseRating
TROSPIUM
European Group for Research In Schizophrenia
Phase 4BBB
Lurasidone
Aziende Chimiche Riunite Angelini Francesco S.p.A
Phase 4BBB
Asenapine
Noven Pharmaceuticals, Inc.
Phase 4BBB
Xanomeline
European Group for Research In Schizophrenia
Phase 4BBB
Opc-34712
Humanis Saglık Anonim Sirketi
Phase 4BBB

View all 50 →

Same molecule, other indications

CLEMASTIN is also rated in:

relapsing-remitting multiple sclerosisDormant
B
Indicative ·
61 / 100
View asset →
multiple sclerosisDormant
B
Indicative ·
60 / 100
View asset →
internuclear ophthalmoplegiaDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →